Precision BioSciences (NASDAQ:DTIL) CEO Sells $145,111.83 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 34,799 shares of the firm’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $4.17, for a total transaction of $145,111.83. Following the completion of the transaction, the chief executive officer directly owned 196,154 shares of the company’s stock, valued at $817,962.18. This represents a 15.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Michael Amoroso also recently made the following trade(s):

• On Monday, November 3rd, Michael Amoroso sold 3,409 shares of Precision BioSciences stock. The stock was sold at an average price of $6.49, for a total transaction of $22,124.41.

Precision BioSciences Stock Performance

Shares of DTIL stock opened at $4.20 on Friday. The company has a fifty day moving average price of $4.55 and a two-hundred day moving average price of $5.12. Precision BioSciences, Inc. has a one year low of $3.75 and a one year high of $8.82. The stock has a market cap of $55.69 million, a P/E ratio of -0.50 and a beta of 1.20. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.45 and a quick ratio of 3.45.

Precision BioSciences (NASDAQ:DTIL) last issued its earnings results on Monday, November 3rd. The company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($1.53). The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $5.40 million. Precision BioSciences had a negative net margin of 11,977.36% and a negative return on equity of 233.77%. During the same quarter last year, the business posted ($2.25) earnings per share. As a group, equities analysts predict that Precision BioSciences, Inc. will post -1.23 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Precision BioSciences in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Precision BioSciences presently has an average rating of “Hold” and an average price target of $60.00.

Institutional Trading of Precision BioSciences

Hedge funds have recently added to or reduced their stakes in the company. Aberdeen Group plc bought a new stake in Precision BioSciences in the 4th quarter valued at $8,897,000. Corient Private Wealth LLC acquired a new position in shares of Precision BioSciences in the second quarter valued at about $425,000. Vanguard Group Inc. increased its position in Precision BioSciences by 21.5% during the third quarter. Vanguard Group Inc. now owns 492,596 shares of the company’s stock worth $2,719,000 after acquiring an additional 87,242 shares during the period. Two Sigma Investments LP increased its position in Precision BioSciences by 407.8% during the third quarter. Two Sigma Investments LP now owns 83,092 shares of the company’s stock worth $459,000 after acquiring an additional 66,729 shares during the period. Finally, Bridgeway Capital Management LLC bought a new stake in Precision BioSciences in the 2nd quarter valued at about $260,000. 37.99% of the stock is owned by institutional investors and hedge funds.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.